Vaccine complacency and dose distribution inequities limit the benefits of seasonal influenza vaccination, despite a positive trend in use


Posted: 2021-09-15 19:00:00
. 2021 Sep 11;S0264-410X(21)01157-9. doi: 10.1016/j.vaccine.2021.08.097. Online ahead of print. Affiliations Expand Affiliations 1 Consultant at Abbott, C.J. van Houtenlaan 36, 1381 CP Weesp, the Netherlands. Electronic address: bram.palache@ziggo.nl. 2 Seqirus Ltd, 63 Poplar Road, Parkville, Victoria 3052, Australia; Department of Immunology and Microbiology, the University of Melbourne, Parkville, Victoria, Australia. Electronic address: Steven.Rockman@Seqirus.com. 3 Seqirus Vaccines, Renaissance Way, Speke, Liverpool L24 9JW, UK. Electronic address: Beverly.Taylor@Seqirus.com. 4 Sanofi Pasteur, 2 Ave Pont Pasteur, Lyon 69007, France. Electronic address: Meral.Akcay@sanofi.com. 5 GSK Vaccines, Av. Fleming 20, 1300 Wavre, Belgium. Electronic address: john.k.billington@gsk.com. 6 International Federation of Pharmaceutical Manufacturers and Associations, Ch. des Mines 9, P.O. Box 195, 1211 Geneva 20, Switzerland. Electronic address: p.barbosa@ifpma.org. Item in Clipboard Abraham Palache et al. Vaccine. 2021. Show details Display options Display options Format . 2021 Sep 11;S0264-410X(21)01157-9. doi: 10.1016/j.vaccine.2021.08.097. Online ahead of print. Affiliations 1 Consultant at Abbott, C.J. van Houtenlaan 36, 1381 CP Weesp, the Netherlands. Electronic address: bram.palache@ziggo.nl. 2 Seqirus Ltd, 63 Poplar Road, Parkville, Victoria 3052, Australia; Department of Immunology and Microbiology, the University of Melbourne, Parkville, Victoria, Australia. Electronic address: Steven.Rockman@Seqirus.com. 3 Seqirus Vaccines, Renaissance Way, Speke, Liverpool L24 9JW, UK. Electronic address: Beverly.Taylor@Seqirus.com. 4 Sanofi Pasteur, 2 Ave Pont Pasteur, Lyon 69007, France. Electronic address: Meral.Akcay@sanofi.com. 5 GSK Vaccines, Av. Fleming 20, 1300 Wavre, Belgium. Electronic address: john.k.billington@gsk.com. 6 International Federation of Pharmaceutical Manufacturers and Associations, Ch. des Mines 9, P.O. Box 195, 1211 Geneva 20, Switzerland. Electronic address: p.barbosa@ifpma.org. Item in Clipboard CiteDisplay options Display options Format Abstract Sustainable demand for seasonal influenza vaccines is a component of national security strategies for pandemic preparedness. However, the ongoing COVID-19 pandemic has revealed many weaknesses in the capacity of countries to design and execute sustainable vaccination programs. An influenza pandemic remains a global threat and yet there is no global monitoring system for assessing progress towards influenza vaccination coverage targets. The International Federation of Pharmaceutical Manufacturers and Associations' (IFPMA) Influenza Vaccine Supply International Task Force (IVS) developed a survey method in 2008 to estimate seasonal influenza vaccination coverage rates, which in turn serves as a crude estimate of pandemic preparedness. It provides evidence to guide expanded efforts for pandemic preparedness, specifically for increasing COVID-19 vaccine immunization levels. Furthermore, the results presented herein serve as a proxy for assessing the state of pandemic preparedness at a global and regional level. This paper adds data from 2018 and 2019 to the previous analyses. The current data show an upward or stable global trend in seasonal influenza vaccine dose distributed per 1,000 population with a 7% increase between 2017 and 2018 and 6% increase between 2018 and 2019. However, considerable regional inequities in access to vaccine persist. Three regions, Africa, the Middle-east, and Southeast Asia together account for 50% of the global population but only 6% of distributed seasonal influenza vaccine doses. This is an important finding in the context of the ongoing COVID-19 pandemic, as distribution of influenza vaccine doses in many ways reflects access to COVID-19 vaccines. Moreover, improving seasonal vaccine uptake rates is critical for optimizing the annual benefits by reducing the huge annual influenza-associated societal burdens and by providing protection to vulnerable individuals against serious complications from seasonal influenza infections. Keywords: Monitoring and evaluation; Pandemic preparedness; Seasonal influenza; Vaccination coverage rates; Vaccination policy; Vaccine recommendations. Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved. Conflict of interest statement Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Abraham Palache reports a relationship with Abbott that includes: consulting or advisory. Abraham Palache, Steven Rockman, Beverly Taylor, Meral Akcay, John K Billington are full-time or contract employees of member companies of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) Influenza Vaccine Supply International Task Force (IVS). The IFPMA IVS member companies develop, manufacture and supply the majority of the world’s influenza vaccines. Representatives of IFPMA IVS member companies may have other financial interests in those companies. Paula Barbosa is a full-time employee of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). [x] Cite Copy Format: Send To [x]

参考サイト PubMed: covid-19



バイオクイックニュース日本語版:COVID-19特集

バイオクイックニュース日本語版
4月 05, 2021 バイオアソシエイツ

匂いが強力に記憶を誘発する理由とは?新研究で初めて神経基盤を特定

マルセル・プルーストの小説「失われたときを求めて」にはマドレーヌで記憶がよみがえり紅茶のカップから記憶が溢れ出てくるという章があるように、匂いは強力に記憶を呼び起こすことができる。 ノースウェスタン大学ファインバーグ医学部の研究者らによって執筆された新論文は、脳がどのように匂いがそれらの記憶を非常に強力に引き出すことを可能にするかについての神経基盤を特定した最初のものである。この論文は、海馬と人間の嗅覚領域との間の独特の接続性を示している。…